David Malcom Rodman Sells 2,170 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock

August 13, 2026 by InsiderTrades.com

Key Points

Insider selling: David Malcom Rodman sold 2,170 Mineralys Therapeutics shares for approximately $58,785 under a pre-arranged Rule 10b5-1 plan, reducing his stake by 4.05% to 51,384 shares.
Weak quarterly results: Mineralys reported a second-quarter loss of $2.85 per share, substantially worse than analysts’ expected loss of $0.55 per share.
Analyst outlook remains mixed but favorable overall: Six analysts rate the stock a Buy, one rates it Hold and one rates it Sell, resulting in a Moderate Buy consensus and an average price target of $49.33 versus a share price near $27.

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 2,170 shares of the firm's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $27.09, for a total transaction of $58,785.30. Following the sale, the insider directly owned 51,384 shares in the company, valued at approximately $1,391,992.56. The trade was a 4.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

There's a Lot to Love About Mineralys' Valentine's Day IPO

David Malcom Rodman also recently made the following trade(s):

On Thursday, July 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $30.30, for a total transaction of $65,781.30.
On Wednesday, June 17th, David Malcom Rodman sold 4,584 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $25.00, for a total transaction of $114,600.00.
On Monday, June 15th, David Malcom Rodman sold 9,890 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $23.81, for a total transaction of $235,480.90.
On Friday, June 12th, David Malcom Rodman sold 6,349 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $23.93, for a total transaction of $151,931.57.
On Wednesday, June 10th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $25.00, for a total value of $54,250.00.
On Monday, May 18th, David Malcom Rodman sold 417 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.55, for a total value of $11,488.35.

Mineralys Therapeutics Stock Performance

MLYS stock opened at $27.05 on Thursday. Mineralys Therapeutics, Inc. has a fifty-two week low of $12.59 and a fifty-two week high of $47.65. The business's 50-day moving average is $26.42 and its two-hundred day moving average is $27.60. The company has a market cap of $2.23 billion, a price-to-earnings ratio of -6.38 and a beta of 0.68.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($2.85) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by ($2.30). Equities analysts predict that Mineralys Therapeutics, Inc. will post -2.3 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Navalign LLC purchased a new stake in Mineralys Therapeutics during the 4th quarter valued at approximately $33,000. KBC Group NV bought a new position in shares of Mineralys Therapeutics during the first quarter worth $33,000. Royal Bank of Canada grew its stake in Mineralys Therapeutics by 262.3% during the fourth quarter. Royal Bank of Canada now owns 1,529 shares of the company's stock valued at $56,000 after acquiring an additional 1,107 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in Mineralys Therapeutics by 1,845.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,101 shares of the company's stock valued at $76,000 after acquiring an additional 1,993 shares during the last quarter. Finally, FNY Investment Advisers LLC lifted its stake in Mineralys Therapeutics by 400.0% in the 2nd quarter. FNY Investment Advisers LLC now owns 2,500 shares of the company's stock worth $67,000 after purchasing an additional 2,000 shares in the last quarter. 84.46% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

MLYS has been the subject of a number of recent research reports. TD Cowen assumed coverage on shares of Mineralys Therapeutics in a research report on Monday, April 27th. They set a "buy" rating for the company. HC Wainwright reissued a "buy" rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. Wall Street Zen cut Mineralys Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, May 9th. Jefferies Financial Group reaffirmed a "hold" rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Mineralys Therapeutics in a research note on Friday, July 17th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Mineralys Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $49.33.

Check Out Our Latest Analysis on MLYS

Mineralys Therapeutics News Roundup

Here are the key news stories impacting Mineralys Therapeutics this week:

Positive Sentiment: Regulatory milestone remains on track: The company reiterated a December 22, 2026 PDUFA target date for lorundrostat, its investigational treatment for hypertension, and said commercial launch preparations are progressing in anticipation of approval. Mineralys second-quarter results and corporate update
Positive Sentiment: Financial flexibility improved: Management highlighted a strong cash position with funding expected to support operations into 2028. Strategic financing initiatives and the repurchase of the Tanabe royalty obligation also strengthen the long-term economics of lorundrostat by reducing a future royalty burden. Mineralys launch readiness and cash runway
Positive Sentiment: New medical leadership: Mineralys appointed cardiovascular medicine executive Dr. Terry Ferguson as chief medical officer. He will oversee medical strategy and late-stage clinical activities ahead of the potential lorundrostat launch. Mineralys appoints chief medical officer
Neutral Sentiment: Short-interest data offered little signal: Reported short interest was zero shares, with a zero-day days-to-cover ratio, suggesting the data does not indicate meaningful short-selling pressure.
Negative Sentiment: Quarterly loss missed expectations sharply: Mineralys reported a second-quarter loss of $2.85 per share, compared with the analyst consensus estimate of a $0.55 loss. The sizable variance may be weighing on the stock, although the company remains focused on its pre-commercial development and launch activities. Mineralys second-quarter earnings call transcript

Mineralys Therapeutics Company Profile

(Get Free Report)

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.